510(k) K250925
K250925 is an FDA 510(k) premarket notification submitted by Fujirebio Diagnostics,Inc. for the device "ADVIA Centaur Cytokeratin Fragment 21-1". The FDA issued a decision of Substantially Equivalent on Dec 16, 2025. The device falls under product code OVK (Cytokeratin Fragments 21-1 Eia Kit), a Class II device regulated under 21 CFR 866.6010. Fujirebio Diagnostics,Inc. has 44 other 510(k) clearances on record.
Clearance details
- Decision
- SESE (Substantially Equivalent)
- Decision Date
- Dec 16, 2025
- Date Received
- Mar 27, 2025
- Clearance Type
- Traditional
- Expedited Review
- No
- Third Party Review
- No
Device classification
- Device Name
- Cytokeratin Fragments 21-1 Eia Kit
- Device Class
- Class II
- Regulation Number
- 866.6010
- Review Panel
- IM
- Submission Type
- 510(k)
The CYFRA 21-1 EIA kit is intended for the quantitative determination of soluble cytokeratin 19 fragments in human serum. The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in lung cancer patients. Serial testing for patient CYFRA 21-1 assay values should be used in conjunction with other clinical methods used for monitoring lung cancer.
Need the full FDA record for Fujirebio Diagnostics,Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.